Entvin (YC S22)’s Post

Every day, the FDA publishes 100s of updates—ranging from old molecule label revisions to new ANDA and NDA approvals. Regulatory professionals and scientists often find themselves overwhelmed, navigating a sea of information from various regulatory bodies. But what if you only received updates tailored to your needs? At Entvin, we’ve built an AI-powered solution that reads through all these updates and flags only the ones that matter to you. For example, today I received an email update about a new NDA approval for Nilotinib Tartrate by Azurity Pharmaceuticals Inc. This 505(b)(2) application introduces a tablet dosage form, distinct from Novartis’ capsule form for Nilotinib Hydrochloride, approved back in 2007. (A 505(b)(2) application is a streamlined FDA approval pathway for drugs that use existing data to support changes like new dosage forms, strengths, formulations, or indications.) With Entvin AI, you won’t miss insights like this—keeping your focus where it truly matters. ➡️ Let Entvin (YC S22) AI streamline your workflows and make data-driven decisions faster.